当前位置: 首页 >> 检索结果
101. Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.
作者: Martin B Leon.;Michael J Mack.;Philippe Pibarot.;Rebecca T Hahn.;Vinod H Thourani.;S H Kodali.;Philippe Généreux.;Samir R Kapadia.;David J Cohen.;Stuart J Pocock.;Yiran Zhang.;Molly Szerlip.;Julien Ternacle.;S Chris Malaisrie.;Howard C Herrmann.;Wilson Y Szeto.;Mark J Russo.;Vasilis Babaliaros.;Tamim Nazif.;John G Webb.;Raj R Makkar.; .
来源: N Engl J Med. 2026年394卷8期773-783页
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-valve replacement (TAVR) and those who had undergone surgical aortic-valve replacement. Longer-term assessments of clinical outcomes and valve durability are needed.
102. Common Diseases in Clinical Cohorts - Not Always What They Seem.
作者: Fedik Rahimov.;Benjamin M Jacobs.;John S Lee.;Naim A Mahi.;Andrew Blumenfeld.;Ammar J Alsheikh.;Ali Abbasi.;Mark Reppell.;Valerie L Pivorunas.;Haukur J Sigurðsson.;Stephen Sawcer.;Heath Guay.;Jeffrey F Waring.;Howard J Jacob.;Nizar Smaoui.
来源: N Engl J Med. 2025年393卷16期1589-1598页
Misdiagnosis or underdiagnosis of rare diseases in patients with diagnoses of common diseases can lead to delayed or inappropriate treatments, thereby complicating the management of both rare and common conditions. Despite advances in molecular diagnostic techniques, the effect of rare diseases on the diagnosis of common diseases in research and clinical trials has not been comprehensively investigated.
103. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
作者: Javier Cortés.;Kevin Punie.;Carlos Barrios.;Sara A Hurvitz.;Andreas Schneeweiss.;Joohyuk Sohn.;Eriko Tokunaga.;Adam Brufsky.;Yeon Hee Park.;Binghe Xu.;Roberto Hegg.;Mafalda Oliveira.;Alessandra Fabi.;Natalya Vaksman.;Theresa Valdez.;Xinrui Zhang.;Catherine Lai.;Sara M Tolaney.; .
来源: N Engl J Med. 2025年393卷19期1912-1925页
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) have limited treatment options.
104. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.
作者: Wenfeng Fang.;Lin Wu.;Xiangjiao Meng.;Yu Yao.;Wei Zuo.;Wenxiu Yao.;Yanyan Xie.;Yu Zhang.;Jiuwei Cui.;Yongchang Zhang.;Xingya Li.;Wu Zhuang.;Jian Fang.;Qiming Wang.;Wei Jiang.;Kai Li.;Yuju Bai.;Yongzhong Luo.;Fang Ma.;Yan Yu.;Wei Zheng.;Zhentian Liu.;Bin Yang.;Rui Ma.;Yong Fang.;Runxiang Yang.;Liyan Jiang.;Jie Hu.;Jiacheng Yang.;Yina Diao.;Xiaoping Jin.;Junyou Ge.;Yunpeng Yang.;Li Zhang.
来源: N Engl J Med. 2026年394卷1期13-26页
Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy.
105. Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
作者: Camilo Jimenez.;Mikkel Andreassen.;Alice Durand.;Sophie Moog.;Andrew Hendifar.;Staffan Welin.;Francesca Spada.;Rohini Sharma.;Edward Wolin.;Joseph Ruether.;Rocio Garcia-Carbonero.;Martin Fassnacht.;Jaume Capdevila.;Jaydira Del Rivero.;Othon Iliopoulos.;Olivier Huillard.;Raymond Jang.;Knut Mai.;Elena Artamonova.;Andreas Hallqvist.;Tobias Else.;Amos Odeleye-Ajakaye.;Alexander Gozman.;Girish S Naik.;Alfredo Berruti.; .
来源: N Engl J Med. 2025年393卷20期2012-2022页
Pheochromocytoma and paraganglioma are neoplasms originating in the adrenal medulla and extraadrenal paraganglia, respectively. Most cases of metastatic pheochromocytoma and paraganglioma are driven by dysregulation of the hypoxia-inducible factor 2α (HIF-2α) pathway. Belzutifan is a HIF-2α inhibitor that may provide antitumor activity in patients with advanced pheochromocytoma or paraganglioma.
106. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
作者: Xinan Sheng.;Gongqian Zeng.;Cuijian Zhang.;Qingyun Zhang.;Jiasheng Bian.;Haitao Niu.;Jun Li.;Yanxia Shi.;Kai Yao.;Bin Hu.;Ziling Liu.;Hong Liao.;Zhixian Yu.;Baiye Jin.;Peng Zhao.;Tiejun Yang.;Xianling Liu.;Yang Qin.;Xueyi Xue.;Xin Gou.;Jian Huang.;Jiang Gu.;Xiaolong Qi.;Lu Zhang.;Guoxian Ma.;Beisong Liu.;Jianmin Fang.;Shusuan Jiang.;Zhisong He.;Aiping Zhou.;Jun Guo.; .
来源: N Engl J Med. 2025年393卷23期2324-2337页
Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific disitamab vedotin as monotherapy and when combined with programmed cell death protein 1 (PD-1)-directed immunotherapy in this cancer.
107. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
作者: Thomas Powles.;Ariel G Kann.;Daniel Castellano.;Marine Gross-Goupil.;Hiroyuki Nishiyama.;Sergio Bracarda.;Jørgen Bjerggaard Jensen.;Lydia Makaroff.;Shusuan Jiang.;Ja Hyeon Ku.;Se Hoon Park.;Oscar Reig Torras.;Dingwei Ye.;Marco Maruzzo.;Andrea Necchi.;Rafael Morales-Barrera.;Emilio Francesco Giunta.;Jae Lyun Lee.;Giampaolo Tortora.;Yüksel Ürün.;Lukasz Dolowy.;Dilek Erdem.;Alvaro Pinto.;Fabricio Grando.;Wei Zou.;Zoe June Assaf.;Jacqueline Vuky.;Viraj Degaonkar.;Elizabeth E Steinberg.;Joaquim Bellmunt.;Jürgen E Gschwend.; .
来源: N Engl J Med. 2025年393卷24期2395-2408页
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)-based detection of molecular residual disease may identify patients at high risk for recurrence after cystectomy who can benefit from adjuvant immunotherapy, thus sparing patients at lower risk from unnecessary treatment burden.
108. Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD.
作者: Frank G Holz.;Yannick Le Mer.;Mahiul M K Muqit.;Lars-Olof Hattenbach.;Andrea Cusumano.;Salvatore Grisanti.;Laurent Kodjikian.;Marco Andrea Pileri.;Frederic Matonti.;Eric Souied.;Boris V Stanzel.;Peter Szurman.;Michel Weber.;Karl Ulrich Bartz-Schmidt.;Nicole Eter.;Marie Noelle Delyfer.;Jean François Girmens.;Koen A van Overdam.;Armin Wolf.;Ralf Hornig.;Martina Corazzol.;Frank Brodie.;Lisa Olmos de Koo.;Daniel Palanker.;José-Alain Sahel.
来源: N Engl J Med. 2026年394卷3期232-242页
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in such persons currently exist. The photovoltaic retina implant microarray (PRIMA) system combines a subretinal photovoltaic implant and glasses that project near-infrared light to the implant in order to restore sight to areas of central retinal atrophy.
109. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
作者: Neal D Shore.;Murilo de Almeida Luz.;Ugo De Giorgi.;Martin Gleave.;Geoffrey T Gotto.;Christopher M Pieczonka.;Gabriel P Haas.;Choung-Soo Kim.;Miguel Ramirez-Backhaus.;Antti Rannikko.;Matko Kalac.;Swetha Sridharan.;Matt Rosales.;Yiyun Tang.;Ronald F Tutrone.;Balaji Venugopal.;Arnauld Villers.;Henry H Woo.;Fong Wang.;Stephen J Freedland.
来源: N Engl J Med. 2026年394卷6期563-575页
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically recurrent prostate cancer. The final analysis of overall survival has not been reported.
110. Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
作者: Paolo A Ascierto.;Michele Del Vecchio.;Barbara Merelli.;Helen Gogas.;Ana M Arance.;Stéphane Dalle.;Charles Lance Cowey.;Michael Schenker.;Caroline Gaudy-Marqueste.;Jacopo Pigozzo.;Iván Márquez-Rodas.;Marcus O Butler.;Anna Maria Di Giacomo.;Oleg Gligich.;Luis De La Cruz-Merino.;Petr Arenberger.;Victoria Atkinson.;Paul Nathan.;Andrew Hill.;Michael Millward.;Leslie A Fecher.;Nikhil I Khushalani.;Paola Queirolo.;Raheela Soomro.;Dhanrajsinh Rathod.;Margarita Askelson.;Melanie Pe Benito.;Devanand Joseph.;James Larkin.
来源: N Engl J Med. 2026年394卷4期333-342页
In the CheckMate 238 trial, patients with resected stage IIIB-C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival.
111. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
作者: Pasi A Jänne.;David Planchard.;Kunihiko Kobayashi.;James Chih-Hsin Yang.;Ying Liu.;Natalia Valdiviezo.;Tae Min Kim.;Liyan Jiang.;Hiroshi Kagamu.;Noriko Yanagitani.;Jialei Wang.;Bivas Biswas.;Artem Poltoratskiy.;Yeni Neron.;Carlos Rojas.;Leona Koubkova.;Carles Escriu.;Doreen A Ezeife.;Helen Mann.;Elena Armenteros-Monterroso.;Yuri Rukazenkov.;Chee Khoon Lee.; .
来源: N Engl J Med. 2026年394卷1期27-38页
The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Results from the planned final analysis of overall survival are needed.
112. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
作者: Xiuning Le.;Tae Min Kim.;Herbert H Loong.;Arsela Prelaj.;Boon Cher Goh.;Lin Li.;Yong Fang.;Shun Lu.;Xiaorong Dong.;Lin Wu.;Yuki Shinno.;Gennaro Daniele.;Tsung-Ying Yang.;Hye Ryun Kim.;Gerrina Ruiter.;Jun Zhao.;Silvia Novello.;Liyun Miao.;Pasi A Jänne.;Koichi Goto.;Dominik Rüttinger.;Tine Descamps.;Jan Christoph Brase.;Weichao Bao.;Rui Li.;Nicoletta Brega.;Paolo Grassi.;Nicolas Girard.;Daniel Shao-Weng Tan.; .
来源: N Engl J Med. 2025年393卷18期1819-1832页
HER2 gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models.
113. Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality.
作者: Fadima Cheick Haidara.;Laura Adubra.;Mahamadou Abdou.;Dagmar Alber.;Ulla Ashorn.;Yin Bun Cheung.;Elaine Cloutman-Green.;Mamadou Diallo.;Camilla Ducker.;Yue-Mei Fan.;Gwydion Gruffudd.;Lotta Hallamaa.;Tiia Haapaniemi.;Rikhard Ihamuotila.;Jane Juma.;Nigel Klein.;Juho Luoma.;Owen Martell.;Akshaya Murugesan.;Collins Okello.;Oumar Samaké.;Cheick Amadou Tidiane Traore.;Taru Vehmasto.;Kaisa Ylikruuvi.;Samba Sow.;Per Ashorn.
来源: N Engl J Med. 2025年393卷15期1498-1508页
Mass administration of azithromycin to children 1 to 59 months of age has been shown to reduce mortality among infants and children in this age group in some areas of sub-Saharan Africa. The largest effects have appeared to be among infants younger than 12 months of age, within 3 months after treatment; this observation motivated the design of the current trial.
114. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
作者: Claire Booth.;Katelyn Masiuk.;Konstantinos Vazouras.;Augustine Fernandes.;Jinhua Xu-Bayford.;Beatriz Campo Fernandez.;Sohini Roy.;Beatrice Curio-Penny.;Jordyn Arnold.;Dayna Terrazas.;Jack Reid.;Kimberly C Gilmour.;Stuart Adams.;Elena Alvarez Mediavilla.;Lana Mhaldien.;Grainne O'Toole.;Rima Ahmed.;Elizabeth Garabedian.;Harry Malech.;Suk See De Ravin.;Theodore B Moore.;Satiro De Oliveira.;Danilo Pellin.;Tsai-Yu Lin.;Thao Thi Dang.;Kenneth Cornetta.;Michael S Hershfield.;Havinder Hara.;Adrian J Thrasher.;H Bobby Gaspar.;Donald B Kohn.
来源: N Engl J Med. 2025年393卷15期1486-1497页
Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a life-threatening inborn error of immunity for which lentiviral gene therapy has been investigated in clinical trials.
115. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
作者: Ronald F van Vollenhoven.;Li Wang.;Joan T Merrill.;Yi Liu.;Chunde Bao.;Fen Li.;Jiankang Hu.;Chenghui Huang.;Jianhong Zhao.;Cibo Huang.;Hanyou Mo.;Wei Wei.;Fu'ai Lu.;Jingyang Li.;Dongbao Zhao.;Wenxiang Wang.;Lin Li.;Qing Zuraw.;Xiaofei Wang.;Xuebin Wang.;Jianmin Fang.;Fengchun Zhang.; .
来源: N Engl J Med. 2025年393卷15期1475-1485页
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) in a phase 2b trial when added to standard therapy.
116. Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.
作者: Hua Tu.;He Huang.;Yanfang Li.;Xiaojun Chen.;Chunyan Wang.;Min Zheng.;Yanna Zhang.;Weidong Zhao.;Yanling Feng.;Ting Wan.;Yongwen Huang.;Aijun Yu.;Weiguo Lu.;Jing Xiao.;Weiwei Shan.;Ping Zhang.;Changkun Zhu.;Danbo Wang.;Hu Zhou.;Jibin Li.;Beihua Kong.;Weiwei Feng.;Xipeng Wang.;Rongzhen Luo.;Xin Huang.;Jundong Li.;Zejian Lin.;Shuzhong Yao.;Jihong Liu.; .
来源: N Engl J Med. 2025年393卷15期1463-1474页
Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer.
117. DB-OTO Gene Therapy for Inherited Deafness.
作者: Vassili Valayannopoulos.;Manohar Bance.;Daniela S Carvalho.;John H Greinwald.;Steven A Harvey.;Akira Ishiyama.;Evie C Landry.;Hubert Löwenheim.;Lawrence R Lustig.;Manuel Manrique.;Robert Nash.;Rubén Polo.;Cedric V Pritchett.;Jay T Rubinstein.;A Eliot Shearer.;Ignacio Del Castillo.;Jeffery J Anderson.;C Eduardo Corrales.;Tera M Quigley.;William J Riggs.;Peter Weber.;Gary Wilson.;Susan C Irvin.;Hazem E Hassan.;Yanping Chen.;Rong Liu.;Meghan C Drummond.;Leah R Sabin.;Bret J Musser.;George D Yancopoulos.;Christos A Kyratsous.;Gary A Herman.;Aris Baras.;Jonathon P Whitton.; .
来源: N Engl J Med. 2026年394卷11期1074-1083页
Genetic deficiency of otoferlin, a protein critical to synaptic transmission by the sensory hair cells of the ear, causes congenital deafness. Medicines to treat the condition are lacking; children typically receive cochlear implants. DB-OTO is a dual adeno-associated virus 1 gene therapy that delivers human OTOF complementary DNA (encoding otoferlin) regulated by a hair cell-specific promoter.
118. Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.
作者: Natalie E Dean.;Amy M Crisp.;Azael Che-Mendoza.;Oscar D Kirstein.;Gloria A Barrera-Fuentes.;James T Earnest.;Henry N Puerta-Guardo.;Matthew H Collins.;Norma Pavia-Ruz.;Guadalupe Ayora-Talavera.;Gabriela González-Olvera.;Anuar Medina-Barreiro.;Wilbert Bibiano-Marín.;Shirin Jabbarzadeh.;M Elizabeth Halloran.;Ira M Longini.;Audrey Lenhart.;Lance A Waller.;Fabian Correa-Morales.;Jorge Palacio-Vargas.;Hector Gomez-Dantes.;Pablo Manrique-Saide.;Gonzalo M Vazquez-Prokopec.
来源: N Engl J Med. 2025年393卷14期1387-1398页
Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of walls and under furniture.
119. Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.
Amid the declining clinical severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and diminishing public uptake of annual coronavirus disease 2019 (Covid-19) vaccines, contemporary evidence on vaccine effectiveness against clinically relevant outcomes is needed.
120. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
作者: Vallerie V McLaughlin.;Marius M Hoeper.;David B Badesch.;H Ardeschir Ghofrani.;J Simon R Gibbs.;Mardi Gomberg-Maitland.;Ioana R Preston.;Rogerio Souza.;Aaron B Waxman.;Grzegorz Kopeć.;Gisela Meyer.;Karen M Olsson.;Wei Fu.;Yaru Shi.;Barry Miller.;Samuel S Kim.;Harald S Mackenzie.;Michela Brambatti.;Mahesh J Patel.;Joerg Koglin.;Alexandra G Cornell.;Marc Humbert.; .
来源: N Engl J Med. 2025年393卷16期1599-1611页
Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial hypertension within the first year after diagnosis are unclear.
|